Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §102 only | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEN, SHARON X | 1 | 56.5% | +32.8% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.2% |
| GONZALES, JOSEPHINE MARIA | 1 | 29.8% | +42.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16765783 | USE AND PRODUCTION OF ENGINEERED IMMUNE CELLS TO DISRUPT NFAT-AP1 PATHWAY TRANSCRIPTION FACTORS | GONZALES, JOSEPHINE MARIA | 4d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18094151 | LIGHT INHIBITORS FOR SCLERODERMA AND SKIN FIBROTIC DISEASE TREATMENT | WEN, SHARON X | 86d overdue |
| 17048059 | MODULATING IMMUNE RESPONSE VIA TARGETING OF OLFACTORY RECEPTOR ACTIVITY | CHERNYSHEV, OLGA N | 51d overdue |
| 16765783 | USE AND PRODUCTION OF ENGINEERED IMMUNE CELLS TO DISRUPT NFAT-AP1 PATHWAY TRANSCRIPTION FACTORS | GONZALES, JOSEPHINE MARIA | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1675 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18094151 | LIGHT INHIBITORS FOR SCLERODERMA AND SKIN FIBROTIC DISEASE TREATMENT | WEN, SHARON X | 1641 | Other | Final Rejection | 86d overdue | Pending | Jan 06, 2023 |
| 17048059 | MODULATING IMMUNE RESPONSE VIA TARGETING OF OLFACTORY RECEPTOR ACTIVITY | CHERNYSHEV, OLGA N | 1675 | §102 | Non-Final OA | 51d overdue | Pending | Oct 15, 2020 |
| 16765783 | USE AND PRODUCTION OF ENGINEERED IMMUNE CELLS TO DISRUPT NFAT-AP1 PATHWAY TRANSCRIPTION FACTORS | GONZALES, JOSEPHINE MARIA | 1631 | §103 | Non-Final OA | 4d overdue | Pending | May 20, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial